Startseite>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> NAFLD & NASH>>MHY908

MHY908

Katalog-Nr.GC44191

MHY908 ist ein potenter dualer Agonist von PPARα und PPARγ.

Products are for research use only. Not for human use. We do not sell to patients.

MHY908 Chemische Struktur

Cas No.: 1393371-39-5

Größe Preis Lagerbestand Menge
500μg
66,00 $
Auf Lager
1mg
111,00 $
Auf Lager
5mg
423,00 $
Auf Lager
10mg
716,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MHY908 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ that increases transcriptional activity of PPARα and PPARγ in a luciferase reporter assay in AC2F rat liver cells when used at a concentration of 5 µM. In vivo, MHY908 (3 mg/kg per day) reduces serum glucose, triglyceride, and insulin levels and improves hepatic steatosis by reducing hepatic triglyceride levels and lipid droplet accumulation in db/db mice and 20-month-old rats. It reduces peroxynitrite and COX-2 levels, reactive oxygen species (ROS) production, and Akt phosphorylation in isolated kidney from 20-month-old rats when administered at a dose of 3 mg/kg. MHY908 inhibits mushroom tyrosinase (IC50 = 8.19 µM). It also inhibits increases in melanin content in α-melanocyte stimulating hormone-induced B16/F10 murine melanoma cells when used at a concentration of 10 µM.

Bewertungen

Review for MHY908

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MHY908

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.